Denosumab and Osteoporosis
Body mass index for postmenopausal women with osteoporosis given six different treatments of Denosumab.
A data frame with 236 observations on the following 2 variables.
a numeric vector
a factor with levels
A clinical study was conducted to see whether an antibody called denosumab is effective in treatment of osteoporosis of postmenopausal women. In the article cited below, researchers reported on a study where women with osteoporosis were randomly assigned into groups that received either a placebo, or a six-month regimen of Denosumab at doses of 14 mg, 60 mg, 100 mg, or 210 mg. The bmi dataset provides data on the body-mass indexes (BMI) of the women in each treatment group.
McClung, M., et al. (2006) Denosumab in Postmenopausal Women with Low Bone Mineral Density. New England Journal of Medicine, 354, pp. 821-831.
1 2 3 4 5